Resilience

National Resilience, Inc., operating as Resilience, is a biomanufacturing contract development and manufacturing organization (CDMO) founded in 2020 to expand domestic capacity for producing complex medicines such as cell and gene therapies, biologics, viral vectors, and aseptic drug products. The company launched publicly on November 23, 2020, with a Series B financing of roughly $750 million and more than $800 million in total capital, backed by ARCH Venture Partners, 8VC, GV, and NEA, among others. Resilience went on to raise a $600 million Series C in August 2021 and a $625 million Series D in June 2022, bringing total equity financing to more than $2 billion. In January 2023, Resilience announced an equity investment from Mubadala Investment Company tied to a new biopharma manufacturing facility in the United Arab Emirates. After a period of rapid facility expansion, Resilience determined in June 2025 that its manufacturing capacity had outpaced industry demand and began winding down six underutilized sites across Massachusetts, California, and Florida, while consolidating operations around its Cincinnati-area hub and a Toronto facility. William S. Marth, previously the company's President and COO, was named CEO in December 2024, succeeding co-founder Rahul Singhvi. To fund the restructuring, existing investors provided $250 million in bridge financing, and in November 2025 Resilience secured up to $825 million in long-term debt financing from Oak Hill Advisors, including a $600 million first-lien commitment. In June 2026, the company announced it would relocate its corporate headquarters from San Diego, California to Blue Ash, Ohio, near its Cincinnati manufacturing hub, adding roughly 200 new jobs at the new site.